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Background: The process of angiogenesis (i.e. the formation of new blood
vessels from pre-existing ones) is fundamental to physiological processes such
as reproduction, development and repair, as well as to pathological conditions
such as tumor progression, rheumathoid arthritis and ocular disorders. The
oncofoetal ED-B domain, a specific marker of angiogenesis, consists of
91 amino acid residues that are inserted by alternative splicing into the
fibronectin (FN) molecule. 
Results: The NMR structure of the ED-B domain is reported and reveals
important differences from other FN type III domains. A comparison of the ED-B
domain with the crystal structure of a four-domain FN fragment shows the novel
features of ED-B to be located in loop regions that are buried at interdomain
interfaces, and which therefore largely determine the global shape of the FN
molecule. The negatively charged amino acids in this highly acidic protein are
uniformly distributed over the molecular surface, with the sole exception of a
solvent-exposed hydrophobic patch that represents a potential specific
recognition site. Epitope mapping with 82 decapeptides that span the ED-B
sequence revealed that three ED-B-specific monoclonal antibodies, which
selectively target newly forming blood vessels in tumor-bearing mice, bind to
adjacent regions on the ED-B surface.
Conclusions: The NMR structure enables the identification of a large surface area
of the ED-B domain that appears to be accessible in vivo, opening up new
diagnostic and therapeutic opportunities. Furthermore, the mapping of specific
monoclonal antibodies to the three-dimensional structure of the ED-B domain, and
their use in angiogenesis inhibition experiments, provides a basis for further
investigation of the role of the ED-B domain in the formation of new blood vessels.
Introduction
Angiogenesis — the sprouting of new blood vessels from
existing vasculature — is a characteristic feature of the
spreading of aggressive solid tumors and is also related to
other diseases, such as rheumatoid arthritis, age-related
macular degeneration and diabetic retinopathy [1]. It is
generally accepted that molecules capable of selectively
targeting newly formed blood vessels would create clinical
opportunities for the diagnosis and therapy of these and
other angiogenesis-associated diseases [2−6].
One of the few markers of angiogenesis described so far is
the ED-B domain of fibronectin [7]. Fibronectins (FNs)
are high molecular mass dimeric glycoproteins present in
the extracellular matrix and in body fluids [8]. FNs inter-
act with collagen, heparin, fibrin and cell receptors of the
integrin family, which are implicated in a wide variety
of cellular processes including cell adhesion, cell migration,
hemostasis, thrombosis, wound healing and oncogenic trans-
formation ([9] and references therein). These versatile
molecules are mosaic proteins containing three different
kinds of structural unit, designated type I, type II and
type III repeats. In addition, type III homology domains
can be found in other proteins of the extracellular matrix
[10]. As a result of alternative splicing, FNs exist in several
polymorphic forms. The B-FN isoform [7] contains the
type III ED-B domain, which is inserted between the
type III modules 7 and 8 (FN7 and FN8). This isoform is
present in foetal and neoplastic tissues as well as in adult
blood vessels undergoing angiogenesis, but is undetectable
in mature blood vessels and in normal adult tissues [11].
Here, we report the nuclear magnetic resonance (NMR)
structure of the ED-B domain in solution. Furthermore,
the epitopes for three monoclonal antibodies that recog-
nize B-FN are identified on the surface of the ED-B struc-
ture by peptide mapping. These monoclonal antibodies are
shown to selectively target newly formed blood vessels in
tumor-bearing mice using infrared photodetection of the
fluorescently labeled antibodies.
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Results
Resonance assignment, collection of conformational
constraints and structure determination
Sequence-specific NMR backbone assignments were
obtained on the basis of sequential nuclear Overhauser
effect (NOE) connectivities [12] established with three-
dimensional (3D) 15N-resolved [1H,1H]-NOE spectroscopy
(NOESY) [13], 3D 15N-resolved [1H,1H] total correlation
spectroscopy (TOCSY) [13], 3D 15N-resolved [1H,1H]-
relayed-NOESY [14] and the 3D amide proton-amide nitro-
gen-β-proton triple resonance experiment (3D HNHB)
[15,16]. The combination of these four experiments yielded
unambiguous sequential connectivities for all spin systems
of the ED-B domain. The chemical shifts of the α and β
protons provided the starting point for complete 1H assign-
ments of all CHn moieties in aliphatic and aromatic side-
chains, which were obtained using 2D [1H,1H]-clean-
TOCSY [17], 2D [1H,1H] correlated spectroscopy (COSY)
[18] and 2D [1H,1H]-NOESY [19] spectra recorded with a
sample in D2O. The sidechain amide proton resonances of
asparagine and glutamine were assigned using intraresidual
NOEs [12]. Stereospecific assignments for the methyl
groups of valine and leucine were obtained via biosyntheti-
cally directed fractional 13C-labeling [20,21], and for three
αCH2, 13 βCH2, one γCΗ2 and one δCH2 groups with the
use of the program FOUND [22]. 
Conformational constraints were obtained from NOE upper
distance limits and from scalar spin−spin couplings. Out of a
total of 1809 NOE cross-peaks assigned, 1001 resulted from
3D 15N-resolved [1H,1H]-NOESY, 798 from 2D [1H,1H]-
NOESY and ten from JR-[1H,1H]-NOESY [23]. Inverse
Fourier transformation of in-phase multiplets from a 2D
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Table 1
Characterization of the energy-minimized NMR structure of
ED-B*.
Quantity 20 Conformers†
Residual distance constraint violations
number ≥ 0.1 Å 1.4 ± 1.0
maximum (Å) 0.10 ± 0.05
Residual dihedral angle constraint violations
number ≥ 2.0° 0.4 ± 0.5
maximum (°) 1.9 ± 0.8
AMBER energies (kcal/mol)
total –2966 ± 62
van der Waals –246 ± 9
electrostatic –3450 ± 65
Rms deviation from ideal geometry
bond lengths (Å) 0.0076 ± 0.0001
bond angles (°) 2.27 ± 0.04
peptide bonds (°) 9.5 ± 0.8
Rms deviation to average coordinates‡ (Å)
N, Cα, C′ (5−95) 0.55 ± 0.14
N, Cα, C′ of β strands§ 0.35 ± 0.09
N, Cα, C′ (5−95) plus 19 best defined
core sidechains 0.60 ± 0.13
all heavy atoms (5−95) 0.83 ± 0.21
*NMR spectra were recorded using a 40 mM NaCl and 20 mM
phosphate buffer solution containing 1.3 mM ED-B (pH 7.0,
temperature 25°C). The input for the structure calculation consisted of
1215 NOE upper distance limits (321 intraresidual, 299 sequential,
144 medium-range and 451 long-range) and 407 dihedral angle
constraints. The average residual target function value for the 20 best
DYANA conformers before energy minimization was 0.82 ± 0.14 Å2.
†For each entry the average for the 20 conformers with the lowest
residual DYANA target function values and the variation among the
20 conformers are given. ‡Average coordinates for the 20 energy-
minimized conformers after superposition for best fit of N, Cα and C′
atoms of residues indicated in parentheses. §Comprising residues 
12−17, 21−27, 34−44, 51−56, 62−66, 73−81, 84−86 and 89−93.
Figure 1
The solution structure of the ED-B domain of fibronectin (FN). (a) Ribbon
drawing of one of the 20 energy-minimized conformers of human ED-B
used to represent the NMR structure. Two β sheets formed by three and
four β strands, respectively, are colored in red and cyan. The N and
C termini are indicated and the β strands are labeled A to G following the
nomenclature used for other FN type III domains [32,52−57]. For the
individual β strands, the first and last sequence positions are indicated.
(b) Superposition of the 20 energy-minimized conformers to obtain the
minimal root mean square deviation (rmsd) of the backbone heavy atoms
of residues 5−95; the polypeptide backbone and the 14 best-defined
core sidechains are shown. The orientation of the molecule and the color
code of the β sheets are the same as in (a). The best-defined core
sidechains (yellow) are those with heavy-atom displacements smaller
than 0.75 Å and include Leu9, Leu12, Ile22, Leu24, Trp26, Ile34, Tyr37,
Ile39, Val41, Ala43, Val55, Val64, Ile75 and Val77.
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Structure
[15N,1H]-COSY spectrum provided 50 3JHNα coupling con-
stants [24], and 27 3JNβ scalar coupling constants were mea-
sured using a modified 3D HNHB experiment [25].
The final input for the torsion angle dynamics program
DYANA structure calculation of the ED-B domain contained
1215 upper distance constraints (321 intraresidual, 299
sequential, 144 medium-range and 451 long-range) and 407
dihedral angle constraints, which were derived from
intraresidual and sequential NOEs and J couplings using
the program FOUND [22]. The small size and small
number of residual violations indicate that the input data
set is self-consistent and show that the constraints are well
satisfied by the structures obtained (Table 1). The global
root mean square deviation (rmsd) values calculated for dif-
ferent residue selections (Table 1) show that overall high
precision of the structure determination has been achieved.
Nonetheless, there is significant variation of the displace-
ments for individual residues along the sequence, with the
regular secondary structure elements showing the highest
precision and some loops, especially loops CC′ and EF,
showing increased structural disorder (Table 1; Figure 1). 
The NMR structure of the ED-B domain
The ED-B domain includes two antiparallel β sheets that
form a β sandwich (Figure 1a). One β sheet is formed by
three β strands (A, B and E) and the other by four β strands
(C, C′, F and G; Figure 1a). The two β sheets enclose a
hydrophobic core of 25 amino acid sidechains. The struc-
ture of the core is very precisely defined in the NMR struc-
ture (Figure 1b; Table 1). Two wide-type β bulges [26] are
found in the structure: one is at the end of β strand A and
involves residues Asp16 and Ile17, and the other is within
β strand G and includes residues Ala87 and Pro88. The
loops AB, CC′ and FG are reverse turns that connect
adjacent antiparallel β strands, whereas the loops BC, C′E
and EF connect β strands in the two different β sheets.
Loops AB and FG are well-defined type I and type II
β turns, respectively; another type I β turn of 9–12 res-
idues precedes β strand A. The conformation of the BC
loop (residues 28−33) is particularly well defined by a dense
network of NOE constraints (Figure 2a), including long-
range NOEs with the slowly exchanging OHη of Tyr37 at
10.3 ppm (Figure 2b), and by two hydrogen bonds —
formed between Oη of Tyr37 and the backbone HN of
Leu29 and the other formed between OHη of Tyr37 and
the backbone carbonyl oxygen of Ser57 (Figure 2a).
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Figure 2
The conformation of the BC loop in the human ED-B domain. 
(a) NOEs and hydrogen bonds involved in positioning the BC loop of
residues 28–33. The hydrogen bonds between the backbone amide
proton of Leu29 and Oη of Tyr37 and between OHη of Tyr37 and the
carbonyl oxygen of Ser57 are shown as green dashed lines. Atoms
involved in specific interactions are color-coded: the amide protons are
indicated in cyan, carboxyl oxygens in red and α-protons in green.
Hydrophobic sidechains are in yellow and polar sidechains in magenta.
NOE constraints are drawn as solid orange lines. The backbone of the
BC loop is in brown and all other backbone segments are in gray.
(b) A strip of 100 Hz width about the OHη chemical shift of Tyr37
along ω2 from a 750 MHz 2D JR-[1H,1H]-NOESY spectrum of ED-B.
The spectrum shows NOE cross-peaks involving the hydroxyl proton of
Tyr37. The other hydrogen atoms involved are identified on the left.
ED-B is highly acidic and contains only two positively
charged residues. The negatively charged residues are
uniformly distributed over the protein surface, except for a
solvent-exposed hydrophobic cluster formed by residues
Ile35, Phe54, Ile78 and Leu80 (Figure 3).
Epitope mapping of anti-ED-B antibodies
The three human antibody fragments CGS-1, CGS-2 and
L19 have been recently isolated. These fragments bind to
the recombinant human ED-B domain as well as to intact
B-FN with comparable affinity [4,9,27]. Using the SPOT
synthesis method [28] the epitopes that are recognized by
these three antibodies were identified. A series of 82 deca-
peptides spanning the 91-residue ED-B sequence were
assayed for their binding to CGS-1, CGS-2 and L19. As
shown in Figure 4, all three antibodies recognize partially
overlapping epitopes that consist of two distinct segments
of the ED-B sequence. Accordingly, CGS-1, CGS-2 and
L19 compete with each other for binding to the ED-B
domain, as demonstrated by real-time interaction analysis
with surface plasmon resonance detection (data not shown)
[29]. Furthermore, CGS-2, but not CGS-1 and L19, is
able to bind ED-B from chicken. This protein differs
from human ED-B only by three amino acid substitu-
tions, Ser31→Ala, Gly49→Ser and Ile50→Val, which lie
within the epitopes for CGS-1 and L19. Mapping of the
epitopes onto the NMR structure of ED-B (Figure 4)
shows that all three antibodies recognize surface areas on
the same side of the ED-B molecule, which comprises
loops AB, BC and C′E and part of β strands B, C, C′ and
E (see Figure 1a).
In vivo targeting of B-FN
In order to determine whether the anti-ED-B antibody L19
is capable of the selective targeting of tumoral neovascula-
ture, we used the infrared photodetection methodology of
Folli et al. [30] in the implementation of Neri et al. [4].
Nude mice bearing the subcutaneously grafted F9 murine
teratocarcinoma [4,9] were injected with an L19 antibody
fragment labeled with the infrared fluorophore Cy7. As a
control, identical nude mice were injected with a simi-
larly labeled antibody fragment of irrelevant specificity,
HyHEL-10. Figure 5 shows infrared fluorescence images
of tumor-bearing mice 24 hours after antibody injection.
For L19, intense fluorescence is observed near the tumor,
whereas after injection with the nonspecific control anti-
body HyHEL-10 no fluorescence localization is observed.
Weak fluorescence outside the immediate environment of
the tumor is observed only for the bladder and liver. The
CGS-1 and CGS-2 antibodies have previously been shown
to be capable of tumor targeting in vivo, using the same flu-
orescence labeling technique [4]. Furthermore, the speci-
ficity of tumor targeting has recently been confirmed by
biodistribution analysis using radiolabeled antibodies [31].
Discussion
The insertion of ED-B may cause intermodular
reorientation in FN
The crystal structure of a fragment of human FN consist-
ing of four FN domains (the seventh to the tenth type III
repeats; FN7−10) [32] reveals a rod-like molecule with
highly variable relationships between the individual pairs
of adjacent domains. In spite of their relatively low degree
of sequence homology, the four domains have highly con-
served global folds and differ only in some of the loop
regions [32]. The relative orientations of adjacents pairs of
domains are fine-tuned by interactions at the interdomain
interfaces, which are largely composed of the loops located
near the N and C termini of each domain [32]. It has been
suggested that particular biological functions are deter-
mined by these interdomain interactions and by the
nature of the surface of the individual domains [33]. The
insertion of the ED-B domain during angiogenic processes
provides the FN molecule with an additional variant protein
surface and with new domain–domain interactions, which
may furnish a basis for novel specific functions. In the fol-
lowing, we compare the ED-B domain with FN7 and FN8,
in an attempt to investigate from both sides how the inser-
tion of ED-B between these two domains might affect the
overall FN structure. 
The superposition of the ED-B domain with FN8
(Figure 5a) reveals that the structures are very similar on
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Figure 3
Solvent-exposed hydrophobic patch on the surface of the human ED-B
domain. The van der Waals surfaces of Ile35, Phe54, Ile78 and Leu80
are shown in yellow, the β strands are in the same colors as in
Figure 1a and the loops are drawn as gray cylinders. The positions of
the N terminus, the BC loop and the individual β strands are identified.
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the level of the polypeptide fold, with the sole exception
of the BC loop, which has a different conformation in the
two domains (Table 2; Figure 6a). In ED-B, hydrogen
bonds with the hydroxyl group of Tyr37 stabilize the
arrangement of this loop (Figure 2a). As the correspond-
ing position in FN8 is occupied by phenylalanine residue,
one has a clearcut rationale for the different arrangement
of the BC loop in ED-B and FN8. In FN7−10, the overall
buried surface area suggests a rigid interdomain relation-
ship between FN7 and FN8 [32], and the interactions
between these two domains include a completely buried
isoleucine residue in the BC loop. This isoleucine residue
corresponds to Ser32 in the ED-B domain, where it is part
of a solvent-exposed polar tetrapeptide segment in the
BC loop, Asn30-Ser31-Ser32-Thr33 (Figure 2a). It seems
unlikely, both from its different conformation and from
the different amino acid composition, that the BC loop of
ED-B would be buried in the FN7−ED-B interface in a
similar fashion to the corresponding loop of FN8 in the
FN7−FN8 interface. The FG loops of FN8 and ED-B
assume similar conformations (Figure 6a), but the two
FN8 aromatic residues tyrosine and histidine, which are
also buried in the interdomain interface with FN7, corre-
spond to Ile81 and Glu85 in ED-B.
In the FN7−10 crystal structure [32], the EF loop of FN7
interacts with the N-terminal end of FN8 through contacts
with a proline and a glycine residue. These residues are
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Epitope mapping and tumor target properties of anti-ED-B antibodies.
The binding of the antibodies (a) CGS-1, (b) CGS-2 and (c) L19 to
each synthetic decapeptide of the ED-B sequence is reported as a
horizontal line. The thickness of the line is proportional to the observed
binding affinity. Four minimal sequences recognized by the antibodies
in the array of synthetic ED-B peptides are colored in red, cyan, green
and magenta. The same colors are used on the right to map these
epitopes onto the three-dimensional structure of ED-B, where the
protein is shown in the same orientation as in Figure 1.
conserved in the ED-B sequence, and the conformation of
the EF loop is very similar in ED-B and FN7 (Figure 6b).
In contrast, the AB loop, which is a type I β turn in ED-B
(as well as in FN8 and FN9), assumes a different confor-
mation in FN7 due to the insertion of one amino acid
(Figure 6b). Moreover, in FN7, FN8 and FN9 a hydropho-
bic residue in the AB loop is buried at the interface with the
N-terminal end of the sequentially following domain,
whereas in ED-B this loop consists exclusively of polar and
negatively charged residues, suggesting that it remains sol-
vent-exposed in intact B-FN. Overall, the detailed struc-
ture comparisons of ED-B with FN7 and FN8 imply that in
spite of the similar individual domain folds, marked dif-
ferences in corresponding loop structures cause the relative
orientation of the pairs of adjoining domains (FN7 and
ED-B, and ED-B and FN8) to differ significantly from the
spatial arrangement of FN7 and FN8 in the FN7−10 crystal
structure [32]. This finding is also supported by the obser-
vation that a specific monoclonal antibody, BC-1, recog-
nizes an epitope in FN7 that is inaccessible in FN, but
becomes unmasked in B-FN [34].
Mapping of accessible surfaces indicates B-FN-recognition
sites on the ED-B surface
The restricted expression of B-FN in adults during angio-
genesis has raised interest in the generation of specific
ED-B binding monoclonal antibodies. Despite consider-
able research efforts, no monoclonal antibody capable of
binding directly to the ED-B domain in B-FN has so far
been isolated using hybridoma technology. Considering the
high level of conservation of the ED-B domain this may be
due to immunological tolerance. Furthermore, polyclonal
antibodies raised against recombinant ED-B recognized
B-FN only after treatment with N-glycanase [35,36]. This
observation suggested that these reagents were directed
against the BC loop, which is the only potential site for
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Figure 5
Targeting of fluorescently labeled antibodies
to the F9 murine teratocarcinoma. The data
were obtained by infrared photodetection
24 h after injection of the labeled antibodies
into nude mice bearing the tumor. The mice
were injected (a) with the specific antibody
L19 and (b) with the system-irrelevant
antilysozyme antibody HyHEL-10. For clarity, a
thin line was drawn around the shape of the
mice. The position of the tumor (T) is
indicated.
T T
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Table 2
Comparison of ED-B with other type III human fibronectin
domains*.
FN7 FN8 FN9 FN10
(26.3%)† (26.3%) (31.8%) (28.5%)
ED-B 1.53 Å‡ 1.56 Å‡ 1.55 Å‡ 1.28 Å‡
3.61 Å§ 2.15 Å§ 3.83 Å§ 5.91 Å§
1.66 Å#
*Comparison between the NMR structure of the ED-B domain and each
of the individual domains in the X-ray structure of FN7−10 [32].
†Percentage identity of the primary structure with human ED-B. Values
after superposition for minimal root mean square deviation (rmsd) of: ‡the
backbone N, Cα and C′ atoms corresponding to the regular secondary
structure elements of ED-B (see Figure 1a); §all N, Cα and C′ atoms; #all
the backbone N, Cα and C′ atoms, but not including the BC loop.
N-linked glycosylation in the ED-B sequence, and thus
seems to be glycosylated in vivo.
Using antibody phage technology [37], the specific anti-
ED-B antibodies CGS-1, CGS-2 and L19 have been iso-
lated. Immunometric assays using B-FN isolated from
WI38VA cells and immunohistochemistry assays performed
on cryostat sections of murine and human tumors showed
these antibodies to recognize recombinant ED-B and nat-
ural B-FN, without prior treatment with N-glycanase, with
comparable affinity [4,9,27].
The results of epitope mapping experiments indicate that
CGS-1, CGS-2 and L19 bind to linear peptides containing
Asn30, the potential site of glycosylation. This residue lies
at the periphery of the antigen surface recognized by the
three antibodies (Figure 4). The fact that all three anti-
bodies bind to B-FN in tumor specimens or B-FN
secreted by transformed cell lines, implies that either
Asn30 is not glycosylated, at least in part, or that glycosyla-
tion of the sidechain of Asn30 does not affect antibody
binding. It remains to be seen how glycosylation at Asn30
would affect interdomain interactions.
The CGS-1, CGS-2 and L19 antibodies can efficiently
target tumoral neovasculature upon intravenous injection
in tumor-bearing mice (Figure 5) [4]. The results obtained
demonstrate that newly formed blood vessels can be dis-
tinguished from mature vessels by specific molecules,
which can find their way to the tumor after injection into
the blood circulation.
Biological implications
Angiogenesis, the sprouting of new blood vessels
from pre-existing vasculature, is a characteristic of the
spreading of aggressive solid tumors and underlies many
other diseases. During angiogenesis in adults the onco-
foetal fibronectin isoform (B-FN) accumulates around
newly forming blood vessels, but is undetectable in
normal tissues. In this isoform, the ED-B domain of
fibronectin is inserted between fibronectin domains FN7
and FN8 by alternative splicing [7]. A specific role of
this domain in angiogenesis has not yet been identified,
but its high level of conservation in different species,
with strict identity of the human, mouse, rat and dog
ED-B domains [9], is clearly indicative of a specific
functional role. 
If B-FN is functionally involved in angiogenesis, the
role of the ED-B domain could be either to provide an
additional variant protein surface for interaction with
one or more specific receptors, or to alter fibronectin
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Figure 6
Comparison of the ED-B domain with the
fibronectin domains FN7 and FN8. Super-
position for minimal root mean square
deviation (rmsd) of the backbone atoms N,
Cα and C′ of one of the 20 energy-minimized
conformers of ED-B (cyan) with individual
domains from the four-domain crystal
structure of FN7−10 (yellow).
(a) Superposition of ED-B with FN8.
(b) Superposition of ED-B with FN7.
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FN7 loop AB
(b)
(a)
ED-B loop BC
FN8 loop BC
Structure
properties by changing the distance and orientation
between fibronectin domains.
A change in the relative orientation of the FN7–ED-B
domains, as compared to FN7–FN8, is strongly sup-
ported by the unusual conformation of the BC loop in
ED-B. Additional support for this difference is provided
by the binding properties of the monoclonal antibody
BC1, which recognizes domain FN7 in B-FN, but not in
fibronectin devoid of the ED-B domain [34].
CGS-1, CGS-2 and L19, three monoclonal antibodies
directed against largely overlapping epitopes on the ED-B
domain, recognize the recombinant ED-B domain and
B-FN with comparable affinity. The three antibodies
can target angiogenesis in vivo and their epitopes are all
located on the same face of the ED-B domain, which con-
tains distinctive features such as polypeptide loops and a
solvent-exposed hydrophobic patch. Therefore, a well-
defined portion of the ED-B molecule is accessible in vivo
and this knowledge should facilitate the design of synthetic
binders for diagnostic and therapeutic applications.
The search for a biological function of B-FN in angio-
genesis, which is strongly suggested by its distinctive
localization around newly forming blood vessels, contin-
ues at an intense pace. The site of B-FN synthesis [38]
and its accumulation around vascular structures suggest
that B-FN might recognize components of the modified
extracellular matrix, and/or receptors on endothelial
cells. The NMR structure and the epitope mapping of
specific binders, combined with studies on the inhibition
of angiogenesis by neutralizing antibodies, now provide a
structural platform for more detailed investigations of the
role of B-FN and its ED-B domain in the sprouting of
new capillaries.
Materials and methods 
Sample preparation
The expression of the recombinant ED-B domain was performed using
the expression vector pFVEDB in TG1 E. coli cells. pFVEDB was
obtained by cloning the gene encoding the ED-B domain, followed by a
stop codon, into the BamHI/BgIII sites of pQE12 (Qiagen). pFVEDB
codes for a protein of 95 amino acids, consisting of the residues Met1,
Arg2, Gly3 and Ser4 followed by the 91 amino acid ED-B domain [7].
Uniformly 15N-labeled samples were obtained using a minimal culture
medium containing (15NH4)Cl (1g/l) as the sole nitrogen source. Biosyn-
thetically directed fractional 13C labeling was obtained by using a minimal
medium containing (15NH4)Cl (1g/l) as the sole nitrogen source, and a
mixture of unlabeled glucose (9 g/l) and [13C6]-glucose (1g/l) as the
sole carbon source.
Light-scattering measurements showed that the protein is monomeric if
dissolved at a concentration of 1.3 mM in 40 mM NaCl and 20 mM
phosphate buffer at pH = 7.0. Thermal denaturation of ED-B under these
conditions was monitored by circular dichroism (CD) spectroscopy,
with the melting point at 73°C. On the basis of these results, all NMR
experiments were recorded with 1.3 mM ED-B samples containing
40 mM NaCl and 20 mM phosphate buffer at pH = 7.0 and 25°C,
either in 90% H2O/10% 2H2O or in 100% 2H2O.
NMR spectroscopy
NMR measurements were performed on Bruker DRX500, DRX600 and
DRX750 spectrometers equipped with four channels. Quadrature detec-
tion in the indirect dimensions was achieved using States-TPPI [39].
Spin-lock pulses [40] or pulsed-field gradients [41,42] were used for
suppression of water and undesired coherence pathways. The pro-
grams PROSA [43] and XEASY [44] were used for data processing and
spectral analysis, respectively. 
Sequence-specific NMR assignments were obtained via sequential NOEs
[12] using 3D 15N-resolved [1H,1H]-NOESY at 750 MHz with a 70 ms
mixing time, 3D 15N-resolved [1H,1H]-TOCSY at 600 MHz with a 70 ms
mixing time, 3D 15N-resolved [1H,1H]-relayed-NOESY at 500 MHz with a
70 ms NOESY mixing time and a 50 ms TOCSY mixing time, 3D HNHB
at 500 MHz, 2D [1H,1H]-TOCSY at 600 MHz with a 85 ms mixing time,
2D [1H,1H]-COSY at 600 MHz, and 2D [1H,1H]-NOESY at 750 MHz with
a 70 ms mixing time, where the last three spectra were recorded with a
sample of ED-B dissolved in 2H2O. NOE distance constraints were
obtained from the aforementioned NOESY data. Some additional NOE
constraints came from JR-[1H,1H]-NOESY at 500 MHz with a 70 ms
mixing time. Vicinal 3JHNα coupling constants were obtained by inverse
Fourier transformation of in-phase multiplets [24] from 2D [1H,15N]-COSY
at 750 MHz. Vicinal 3JNβ scalar coupling constants were measured from
a modified HNHB experiment [25] at 500 MHz. Stereospecific assign-
ments for the isopropyl methyl groups of valine and leucine were
obtained using biosynthetically directed fractional 13C labeling [20,21].
Structure calculation
The final round of DYANA structure calculation was started with 50 ran-
domized conformers. The standard annealing protocol [45] was used
with 10,000 torsion angle dynamics steps. The 20 conformers with the
smallest residual target function values were subjected to restrained
energy minimization using the AMBER all-atom force field [46] as
implemented in the program OPAL [47]. The pseudo-energy terms for
distance constraints and dihedral angle constraints were calibrated
such that violations of 0.10 Å and 2.5°, respectively, correspond to an
energy of kBT/2 at room temperature [48]. The restrained energy mini-
mization was carried out in a shell of water molecules with a minimal
thickness of 6 Å, performing a total of 1500 steps of conjugate gradi-
ent minimization for each conformer. The dielectric constant was 1, and
no cut-off for non-bonded interactions was applied. The resulting
20 energy-refined conformers are used to represent the solution struc-
ture of ED-B. A representative unique structure of ED-B was identified
as the one with the lowest rmsd value to the mean structure obtained
by averaging the coordinates of the 20 energy-minimized conformers
after superposition of the backbone atoms of residues 5−95. This
energy-minimized conformer is utilized in all color figures that display a
single conformer. The program MOLMOL [49] has been used for rmsd
calculations and for the preparation of color figures. 
Epitope mapping
Simultaneous parallel solid-phase synthesis of decapeptides span-
ning the ED-B sequence was performed manually with the SPOT
kit (Genosys Biotechnologies Inc., Cambridge, UK), according to the
manufacturer’s instructions. The Asp-Tyr-Lys-Asp-Asp-Asp-Lys peptide,
which is recognized by the M2 antibody (Sigma, Buchs, Switzerland),
was also synthesized on cellulose and included in the peptide series
as a positive control.
Binding assays were performed with recombinant ScFv antibody
fragments [9,28]. As a negative control, an irrelevant anticytomegalo-
virus antibody was used [50]. After the immunometric reaction, the
cellulose filters were imaged with a scanner. Spot intensity was
obtained by pixel integration, and classified as strong, medium and
weak, using arbitrary thresholds.
Real-time interaction analysis was performed with a BiaCORE™ instru-
ment [4,29]. Binding of CGS-1, CGS-2 and L19 to human B-FN and
chicken B-FN was performed according to Carnemolla et al. [9].
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In vivo tumor targeting
Nude mice at age 8–12 weeks were injected subcutaneously with
4 × 106 cells of the mouse teratocarcinoma F9 (ATCC, Rockville, MD).
The ScFv(L19) antibody fragment and an ScFv antibody fragment spe-
cific for hen egg white lysozyme (HyHEL-10) [51] were labeled with the
infrared fluorophore Cy7 (Amersham, UK) [4]. In total, six mice were
injected in the tail vein with 150 µl of Cy7-labeled antibody solution in
phosphate-buffered saline (PBS) when the tumors had reached a diam-
eter of approximately 0.5 to 1 cm. Mice were imaged at regular time
intervals with a home-built mouse-imager [4]. The procedures were
performed according to the Project Licence ‘Tumour Targeting’ issued
to D Neri (Veterinäramt des Kantons Zürich, Bewilligung 53/97).
Accession numbers
The atomic coordinates have been deposited with the Brookhaven
Protein Data Bank with accession code 2FNB. The chemical shift list
has been deposited with the BioMagRes Bank, code 4283.
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